Liver Cancer

After 10 years without a new drug for liver cancer, two approvals and a promising pipeline are changing the landscape.

Treatment with the PD-1 inhibitor Keytruda (pembrolizuumab) elicited promising progression-free survival (PFS) and overall survival (OS) results in patients with advanced hepatocellular carcinoma (HCC) who received previous treatment with Nexavar (sorafenib), according to phase 2 findings.

“Patients with advanced hepatocellular carcinoma often have a poor prognosis and limited treatment options following prior systemic therapy,” lead investigator Ghassan K. Abou-Alfa, M.D.

People treated for liver cancer at an inner-city hospital experienced better survival odds if they had private health insurance, and also if they were married, according to the results of a recent study that considered how socioeconomic factors affect health outcomes for those with the disease.

The liver cancer treatment field has remained stagnant for years, but new agents are destined to enter the field in the near future, Ghassan K. Abou-Alfa, M.D., says.

Blue Faery, the Adrienne Wilson Liver Cancer Association, is a nonprofit corporation founded in 2002, with the intent to prevent, treat and cure primary liver cancer – particularly HCC – through research, education and advocacy. Its name, inspired by Adrienne, has a unique background.

A panel of international oncology experts recently met to exchange thoughts on developments in the field of hepatocellular carcinoma (HCC), the most common form of liver cancer. They discussed screening and staging issues, treatment of advanced HCC and results of recent clinical trials.

Liver cancer diagnoses have increased in the past 25 years, but researchers are hopeful that they will start to drop.

For those with hepatitis B, taking an aspirin once a day could reduce the risk of getting liver cancer.

A free two-day workshop will train people who want to raise awareness of liver diseases and influence public health policy to address their concerns.

Overall survival (OS) was improved when patients with advanced liver cancer took Cabometyx (cabozantinib), compared to those who were given placebo. All participants previously took Nexavar (sorafenib).

After nearly a decade with no new therapies, new drugs to treat liver cancer are showing great promise, according to Steven R. Alberts, M.D.

Opdivo (nivolumab) was granted FDA approval for the treatment of hepatocellular carcinoma (HCC) – regardless of PD-L1 status – for patients who have previously been treated with Nexavar (sorafenib).

Opdivo (nivolumab) was granted a priority review designation by the Food and Drug Administration (FDA) to treat some patients with liver cancer.

The Food and Drug Administration (FDA) has approved Stivarga as a second-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who have previously received Nexavar.

Understanding liver cancer is a crucial step toward the prevention of this rare condition.

Liver cancer diagnoses and mortality have been rising, but new treatments are designed to help reverse the trend.